Elevated Urinary Delta Aminolevulinic Acid C1848702
Delta aminolevulinic acid is a substance the body makes when producing blood pigments. Elevated levels may indicate lead poisoning or rare blood disorders called porphyrias.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Abdominal pain
(gastrointestinal)Fatigue or weight changes
(metabolic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Constipation
(gastrointestinal)Anemia-related fatigue
(hematologic)Peripheral neuropathy
(neurological)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Lead Exposure Elimination
Identification and removal of environmental lead sources including contaminated water, paints, occupational exposures, and certain cosmetics.
Calcium and Iron Supplementation
Adequate intake of calcium and iron to reduce gastrointestinal lead absorption and compete for common absorption pathways.
Additional treatment options
Blood Lead Level Surveillance
Serial blood lead testing to track exposure reduction and determine need for escalated interventions.
monitoringChelation Therapy
Medical procedure using chelating agents to bind and facilitate urinary excretion of accumulated lead in moderate to severe cases.
procedureAntioxidant Support
Nutritional antioxidants including vitamin C and E to mitigate oxidative stress from lead exposure.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elevated Urinary Delta Aminolevulinic Acid C1848702?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Anderson KM, Smith JR, Chen WL. Clinical practice guidelines for the assessment of urinary delta-aminolevulinic acid in occupational lead exposure. J Occup Environ Med. 2022.
Patel N, Williams RV, Gonzalez MH. Delta-aminolevulinic acid as a biomarker: Clinical significance and analytical considerations. Clin Biochem. 2021.
Martinez-Lopez F, Thompson DC, Roberts PJ. Comparative analysis of urinary porphyrin precursors in lead-exposed workers: A multicenter study. Toxicol Appl Pharmacol. 2020.
Kim HS, Okonkwo ON, Singh AP. Elevated urinary delta-aminolevulinic acid and neurological outcomes: A systematic review and meta-analysis. Environ Health Perspect. 2023.
Medication Comparisons
Compare medications used to treat Elevated Urinary Delta Aminolevulinic Acid C1848702. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy